Symbolbild · KI-generiert
Enanta Pharmaceuticals, Inc.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
Enanta Pharmaceuticals is a biotechnology company specialising in anti-infectives and virology. The company develops small-molecule compounds against hepatitis B virus, RSV and other viral diseases, and has previously contributed compounds to hepatitis C combination therapies. Revenues to date have been derived primarily from licensing and royalty arrangements.
Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.
Share price
Price data from TradingView, possibly delayed. Not investment advice.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| Enanta Pharmaceuticals, Inc. | ENTA | NASDAQ | 366 Mio. USD |
| Prelude Therapeutics Incorporated | PRLD | NASDAQ | 366 Mio. USD |
| Abeona Therapeutics Inc. | ABEO | NASDAQ | 366 Mio. USD |
| Century Therapeutics, Inc. | IPSC | NASDAQ | 364 Mio. USD |
| Tenax Therapeutics, Inc. | TENX | NASDAQ | 363 Mio. USD |
| Mobia Medical, Inc. | MOBI | NASDAQ | 372 Mio. USD |
| Emergent BioSolutions Inc. | EBS | NYSE | 373 Mio. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.